Citigroup Boosts Health Catalyst (NASDAQ:HCAT) Price Target to $10.50

Health Catalyst (NASDAQ:HCAT) had its target price hoisted by Citigroup from $9.00 to $10.50 in a research note issued to investors on Wednesday,Benzinga reports. Citigroup currently has a buy rating on the stock.

HCAT has been the topic of several other reports. Piper Sandler decreased their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Stephens decreased their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. JPMorgan Chase & Co. raised their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Finally, Evercore ISI raised their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.71.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $7.65 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average price of $8.16 and a two-hundred day moving average price of $7.22. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a market capitalization of $465.50 million, a P/E ratio of -5.67 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter last year, the business posted ($0.22) earnings per share. The business’s revenue was up 3.5% compared to the same quarter last year. As a group, research analysts expect that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the transaction, the chief operating officer now directly owns 129,690 shares of the company’s stock, valued at $998,613. The trade was a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,068 shares of company stock valued at $257,555. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HCAT. Quest Partners LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at approximately $34,000. Nisa Investment Advisors LLC raised its stake in shares of Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP raised its stake in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC purchased a new stake in shares of Health Catalyst during the third quarter valued at approximately $59,000. Finally, Perfromance Wealth Partners LLC purchased a new stake in shares of Health Catalyst during the second quarter valued at approximately $64,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.